Format

Send to

Choose Destination
Ann Oncol. 2018 Jul 1;29(7):1541-1547. doi: 10.1093/annonc/mdy155.

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.

Author information

1
Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
2
Institute of Oncology, Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv, Israel.
3
Sarah Cannon Research Institute, Nashville, USA.
4
Department of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.
5
Medical Oncology, Netherlands Cancer Institute and BOOG Study Center, Amsterdam, the Netherlands.
6
Division of Oncology, Sheba Medical Center, Ramat Gan, Israel.
7
Department of Medical Oncology, Institut de Cancérologie de l'Ouest/René Gauducheau, Saint-Herblain, France.
8
Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
9
Department of Medicine, Duke University Medical Center, Durham.
10
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA.
11
Department of Gynecology, University of Ulm, Ulm, Germany.
12
Department of Oncology, Tom Baker Cancer Centre, Calgary, Canada.
13
Department of Surgery, Oncology and Gastroenterology and Division of Medical Oncology; University of Padua and Istituto Oncologico Veneto, IRCCS, Padua, Italy.
14
Department of Medicine, Vanderbilt-Ingram Cancer Center, Nashville, USA.
15
Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh, UK.
16
Medical Oncology; Novartis Pharmaceuticals Corporation, East Hanover, USA.
17
Texas Oncology-Baylor Charles A. Sammons Cancer Center and The US Oncology Research Network, Dallas, USA.

Abstract

Background:

The phase III MONALEESA-2 study demonstrated significantly prolonged progression-free survival (PFS) and a manageable toxicity profile for first-line ribociclib plus letrozole versus placebo plus letrozole in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer. Here, we report updated efficacy and safety data, together with exploratory biomarker analyses, from the MONALEESA-2 study.

Patients and methods:

A total of 668 postmenopausal women with HR+, HER2- recurrent/metastatic breast cancer were randomized (1 : 1; stratified by presence/absence of liver and/or lung metastases) to ribociclib (600 mg/day; 3-weeks-on/1-week-off; 28-day treatment cycles) plus letrozole (2.5 mg/day; continuous) or placebo plus letrozole. The primary end point was locally assessed PFS. The key secondary end point was overall survival (OS). Other secondary end points included overall response rate (ORR) and safety. Biomarker analysis was an exploratory end point.

Results:

At the time of the second interim analysis, the median duration of follow-up was 26.4 months. Median PFS was 25.3 months [95% confidence interval (CI) 23.0-30.3] for ribociclib plus letrozole and 16.0 months (95% CI 13.4-18.2) for placebo plus letrozole (hazard ratio 0.568; 95% CI 0.457-0.704; log-rank P = 9.63 × 10-8). Ribociclib treatment benefit was maintained irrespective of PIK3CA or TP53 mutation status, total Rb, Ki67, or p16 protein expression, and CDKN2A, CCND1, or ESR1 mRNA levels. Ribociclib benefit was more pronounced in patients with wild-type versus altered receptor tyrosine kinase genes. OS data remain immature, with 116 deaths observed; 50 in the ribociclib arm and 66 in the placebo arm (hazard ratio 0.746; 95% CI 0.517-1.078). The ORR was 42.5% versus 28.7% for all patients treated with ribociclib plus letrozole versus placebo plus letrozole, respectively, and 54.5% versus 38.8%, respectively, for patients with measurable disease. Safety results, after a further 11.1 months of follow-up, were comparable with those reported at the first analysis, with no new or unexpected toxicities observed, and no evidence of cumulative toxicity.

Conclusions:

The improved efficacy outcomes and manageable tolerability observed with first-line ribociclib plus letrozole are maintained with longer follow-up, relative to letrozole monotherapy.

Clinical trials number:

NCT01958021.

PMID:
29718092
DOI:
10.1093/annonc/mdy155
Free full text

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for Edinburgh Research Explorer, University of Edinburgh
Loading ...
Support Center